35 Gatehouse Drive
27 articles about Skyhawk Therapeutics
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
Tyler Jacks, Ph.D., head of the Koch Institute for Integrative Cancer Research at MIT, joins as Chair of Skyhawk's Scientific Advisory Board
Skyhawk and Merck will partner to discover and develop innovative RNA-binding small molecules that can form treatments for neurological diseases and cancer.
Skyhawk Therapeutics Announces Agreement with Takeda to Develop Novel Small Molecule RNA Splicing Modifiers for Neurodegenerative Diseases
Skyhawk will use its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases. In exchange Takeda will pay Skyhawk an upfront payment, future milestone payments and royalties.
BioSpace Movers and Shakers: Feb. 15
2/15/2019Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs successfully to patients.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk's SkySTAR™ platform